Introduction
============

Rapid and accurate diagnoses, paired with appropriate and effective interventions, are important to stemming the disease process, maintaining economically feasible care and reducing long-term morbidity of infected patients. Sepsis is recognized as a major cause of morbidity and mortality in infected patients and is estimated to occur in 300 cases per 100,000 people per year in the United States and 18 million cases occur per year worldwide ([@B2]; [@B9]). Systematic approaches to early sepsis identification and intervention including timely broad-spectrum antibiotic administration and adequate fluid volume resuscitation have yielded definite improvements in patient outcomes and health care resource utilization. It has been recognized that one of the limiting factors in treatment of sepsis in the hospital setting is the timeliness of pathogen identification and implementation of appropriate antimicrobial therapy ([@B17]). A recent review and meta-analysis of mortality of patients presenting to the emergency department and diagnosed with sepsis indicated that immediate antibiotic administration reduced patient mortality by up to 33% ([@B9]). The current "gold standard" of sepsis microbial identification is blood culture, which takes between 2 and 5 days for a definitive species identification. Antimicrobial agent susceptibility for the given organism is obtained within this same timeframe. However, in the period it takes for final culture results, administration of broad-spectrum antibiotics is provided ensure organism eradication. Improving upon this method of non-specific antimicrobial administration and lengthy identification period is achieved with fast and precise species identification as well as antibiotic resistance gene identification. Any delay in successful treatment has consequences for the patient. Long-term medical problems include increased health care costs due to difficulty in pathogen eradication, as microbial populations gain strength against future drug administration.

Treatment of systemic microbial infections is complicated by the fact that the use and overuse of antibiotics has led to the rise in antimicrobial resistant pathogens. Bacteria develop resistance to antibiotic treatments by mutating the genes targeted by them or acquisition of resistance genes from other bacteria. Together, these problems are compounded by the development of multi-drug resistant "super bugs" that have increased pathogenicity and drive up patient morbidity, mortality and health care costs. Methicillin-resistant *Staphylococcus aureus* (MRSA) and Vancomycin-resistant Enterococcus (VRE) are just two examples of commonly encountered causes of sepsis that pose difficulty in eradication by antibiotic therapy ([@B11]). By identifying the organism(s) responsible for infection, physicians could potentially tailor a specific antibiotic regimen to the pathogen at hand, facilitating immediate and optimal treatment to achieve early goal-directed therapy of patients on a level not previously achieved, while preserving broad-spectrum antibiotics for cases in which they are crucial for patient recovery.

Traditional clinical microbiology has relied upon culture-based methods to identify clinical pathogens, but microbial species can be identified using non-culture based methods by using modern techniques (PCR or mass spectroscopy). Pathogen identification is simplified by the fact that a small number of pathogens are the cause of sepsis in the majority of septic patients (Supplementary Table [1](#SM4){ref-type="supplementary-material"}). Previous attempts at achieving the goal of rapid pathogen identification have been met with moderate success using a multiplex PCR approach; however, this technique is somewhat challenging given the technical expertise and limitations involved with this diagnostic approach ([@B3]; [@B21]). Recent publications aimed at rapid diagnostics offer convincing results by using either culture, DNA extraction follow by real-time PCR for specific detection of uropathogens ([@B22]), or labor intensive gas chromatography -- mass spectroscopy based diagnostics for respiratory pathogens ([@B23]).

In 2000, Notomi and colleagues described a method of DNA amplification without requiring temperature cycling called loop-mediated isothermal amplification (LAMP) ([@B14]). LAMP technology dramatically decreases the time to detection of low abundance DNA templates, typically lowering the threshold for identification from approximately 3 h by traditional PCR to less than 30 min using LAMP ([@B20]).

Briefly, LAMP reactions allow amplification of template at a target temperature between 60 and 65°C utilizing a polymerase enzyme with high strand displacement and replicative activity amplifying two to three sets of DNA primers. LAMP generally employs at least four primers targeting six distinct regions on the gene to maximize specificity. The LAMP reaction produces copious amounts of DNA product, and when carried out with fluorescent or colorimetric analysis the initial target copy number can be determined ([@B15]). As previously reviewed ([@B25]), one of the main advantages of LAMP is the potential for amplification with minimal sample preparation. Studies have shown LAMP from positive blood cultures and DNA purification for MRSA ([@B13]), and for *Chlamydia trachomatis* from urine after minimal pre-processing ([@B7]). In our own previous studies, minimal inhibition was observed in blood, saliva, and urine samples spiked with bacterial pathogens ([@B19]). Thus, LAMP has high potential in the field of medical diagnostics due to minimal sample processing and rapid DNA amplification. LAMP has also been previously demonstrated for detection of the Human Immunodeficiency Virus, *Mycobacterium tuberculosis*, ([@B6]), *Plasmodium falciparum* ([@B16]), *Bacillus anthracis* ([@B5]), *Pseudomonas aeruginosa, Escherichia coli* ([@B26]), Zika Virus ([@B24]), *Clostridium difficile* ([@B8]), and *Acinetobacter baumanii* ([@B12]), to name just a few.

The goal of our study was to develop a rapid test for the presence of common infectious pathogens in human clinical samples with minimal sample processing. We targeted microbes more commonly present in Lansing, MI area hospital patients and compared two separate methodologies to determine detection limits with unique genes characteristic of each microbe. In Step 1, clinical pathogen concentrations were estimated using both a fluorescent-based thermocycler unit (Roche LightCycler 96) and a parallel visual discrimination test utilizing EBT Dye-based reaction color change. In Step 2, we analyzed the presence of molecular targets in patient samples using the In-Dx panel against hospital culture methods from prospectively collected clinical patient samples across clinical culture types.

Results
=======

Analytical Performance of LAMP PCR
----------------------------------

Single gene targets were selected for comparative quantification of pathogens to enable to effectively rule in or rule out the presence of each pathogen (**Table [1](#T1){ref-type="table"}**). Primers were designed to be exclusive to one organism of interest except for *mecA* which is a generalized antibiotic resistance gene target with known associations to a number of clinical pathogens including *S. aureus* and *S. epidermidis*, a coagulase-negative *Staphylococcus* species which has been clinically recognized as a commensal skin contaminant, an opportunistic pathogen, and potential microbial gene-transfer reservoir ([@B4]; [@B18]).

###### 

In-Dx target organisms by genus and species, target primers, NCBI sequence accession code and sensitivity of assays in Colony Forming Units (CFU) × 10ˆ3 per mL of reaction derived from purified DNA, with *in vitro* dilution from urine and blood results with in-Dx LAMP nucleotide primer sequences.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                 Purified       Urine                      Blood            Blood                                                                                                                                                           
  ---- ------------------------------ -------- ----------------------------------- ------------- -------------- -------------------------- ---------------- -------------- ------------------------------ ----------------------------- --------------------------- --------------------------- --------------------------- -----------------------
  1    *Escherichia coli*             pflB     Formate c-acetyl- transferase 1     LT906474.1    50 pg, 22 m    110 × 10ˆ3\                400 × 10ˆ3\      5 pg, 18 m     TCGCCGCTAAAGTGTCCATCGAT\       GCGGCAGTTTTTCAGACCACAGCC\     TCTTCTCTGCAGTATGAGAACGAT    AATGGTCATGTTCGGTTCCG        GGCTTACGCAGCAAGCAATA        GGTCGTACCCTGGTTACCA
                                                                                                                CFU/mL, 30 m               CFU/3 mL, 14 m                  GTTGAAGTCCGGACGCA              TGAACACCCTGTACACC                                                                                                 

  2    *Staphylococcus aureus*        LDH1     Lactate dehydrogenase               NC_002951.2   500 fg, 25 m   80 × 10ˆ3 CFU/mL, 30 m     not tested       5 pg, 17 m     TTGTACCAGAACCTATAACACGTTCCA\   TATTGTTAAGCGAAGCGTTCGAACCA\   ACCAGAGAATTTCCATGTTGCA      TGTTGCGCCACGTAGCG           TGATGGTATTTTCTTGGTAGCT      CCATACTGGTAATTCAGTGTC
                                                                                                                                                                           AATCCTGTTGATATTTTAGCGTA        TGTTCACCAATAATTTGAG                                                                                               

  3    *mecA*                         mecA     Penicillin binding\                 AY894415.1    5 pg, 27 m     40 × 10ˆ3 CFU/mL, 38 m     Not tested       5 pg, 17 m     AATGCAGAAAGACCAAAGCATAC\       TGACGCTATGATCCCAATCTAACT\     TTTAAAATCAGAACGT\           CCACATACCATCTTCTT\          ATCTCATATGCTGTTCCTGTA       AAAAAACGAGTAGATGCTCAA
                                               protein 2                                                                                                                   ATGCCAATTCCACATTGTTTCG         ACTACGGTAACATTGATCGC          GGTAAAATTTTAGAC             TAACAAAATTAAATTG                                        

  4    *Enterococcus faecalis*        BckdE1   Branched-chain alpha-keto acid      AF149712.1    5 pg, 22 m     150 × 10ˆ3 CFU/mL, 30 m    Not tested       5 pg, 27 m     GGAAGGTTTACTCGTAACAGAAG\       CGTTTTCTTAGCTGCAGCACTG\       AATAAAGAAGGCAGCGTGATGA      CGCGATCTAAAGGATATAATGAGCG   TGCATCTAAATCAAAAGAGCA       GGAAAAACTAGCCGCTGAA
                                                                                                                                                                           ACGAAATCATTGCGCAATTTCAC        GAATTGATGCCGAAATCG                                                                                                

  5    *Enterococcus faecium*         Fms14    LPXTG family cell surface protein   NC_017960.1   5 pg, 18 min   60 × 10ˆ3 CFU/mL, 38 min   Not tested       500 fg, 30 m   GAATGCGCTGGAGTGCTTGAAAC\       AACGCCAGTTATTCAACGGTATTA\     CGATTGGTTCGTCCAGCTTTTCCA    CGTCTTGGGCCAACAGCTACG       CTGATACAGAAGATTCCGCT        CGTTTTCAACTTCTCCGC
                                                                                                                                                                           GTAGCGAAGAAAATGAGA             GGATAGATATATTCATAGGGGTC                                                                                           

  6    *Klebsiella pneumoniae*        Khe      Hemolysin gene                      AF293352.1    5 pg, 25 m     50 × 10ˆ3 CFU/mL, 30 m     Not tested       5 pg, 36 m     GCTCAATCCCGGCTATGCCGTC\        GCGGTTGTACTTCTTGTTGGCCC\      ATCGTTGGGTTGACCATCCG        AGACGAACTTCCTGCTCGGTGTTAT   ACTTTTTCCGCGGCTTACC         GGGTTTTCCCGCTGGTAC
                                                                                                                                                                           GTGTGGACCGAAGAACT              ATCTGCCACACCTTTCTCA                                                                                               

  7    *Streptococcus agalactiae*     CspA2    Cell surface protease               CP016391.1    5 pg, 40 m     500 × 10ˆ3 CFU/mL, 50 m    Not tested       5 pg, 30 m     CAATAGCTTTAACATAAAGGGCTGGG\    CGTTAAACTCGGTGCTGATAGCAT\     CCAGTTCCTCTTTTTTCATCAGAGA   TAGGTGGAGCTAATGGCTCTT       CTATGGTGTTGCTCCTGAA         AGCGAGTCTAGCCATCTC
                                                                                                                                                                           CACAAGTAATGTTTATGAGAGTC        TATAAGTCGGTCATCGGC                                                                                                

  8    *Staphylococcus epidermidis*   gehD     Lipase precursor                    AF090142.1    5 pg, 17 m     5 × 10ˆ3 CFU/mL, 20 m      Not tested       5 pg, 13 m     GCACCATAATCTACTCTTCCACCTT\     GGTCACAAGCGTTATGGCAGATGT\     GTTCAACAGCACGGTCATAATTG     ACATATGAAGGCATCATGCCTGA     TTACCGAGTTCACGAAGC          ACCCATACTATGTCCAACAAG
                                                                                                                                                                           CAATGTAGGAGCATTTAGCA           ATCTTTTTACCTGGTTCC                                                                                                

  9    *Streptococcus pyogenes*       MstA     M protein                           AE004092.2    5 pg, 20 m     8 × 10ˆ3 CFU/mL, 25 m      Not tested       5 pg, 14 m     ACGGCAAAGTAATCTTTGTTTTTC\      ACTTGGAAGGTGCAAGCGAAAAATG\    GCATTTTTCACTAGTTTGGTGAACC   GAAAAGAAGATCCACATGCTTGGT    GCTGATGTGATTTTCTATAATGGTA   CAATCAATTGTTTGGCAATGT
                                                                                                                                                                           GCAATCTAGAAGATGGTGGGC          ATTCCGTTTTCGAGAT                                                                                                  

  10   *Proteus mirabilis*            DiaA-2   Tyrosine decarboxylase              CP004022.1    50 fg, 20 m    20 × 10ˆ3 CFU/mL, 45 m     Not tested       50 pg, 26 m    CAATTTCATCGGGAATATTCCCCT\      TCCAATCAGCACCTGCAGTTGC\       TTCTGGGCACAGTTTTGGCGG       GGGGGATCCATCAGCTATATGCTTT   CCTACGGGGATTGTTTGT          AGCTTCCCATTGATTTTGAG
                                                                                                                                                                           CGATTAAGCCGTTTTCTCGC           GCATTGTCCATACCCAA                                                                                                 

  11   *Pseudomonas aeruginosa*       ArcC     Carbamate kinase                    NC_002516.2   5 pg, 15 m     30 × 10ˆ3 CFU/mL, 25 m     Not tested       50 p, 24 m     AACTTGTCGCCGTCCGGGGGA\         GAAGCGGATCTTCGAGATCCGCA\      GATGCTCCAGCCCTTCTCG         CCGGTGAAGTGGCTGCT           ATCGGCCCGGTCTACTCC          TCGTACATGGTCGGGATACC
                                                                                                                                                                           AGAAGCCGAGCGCCTG               GATGACGATGGTGCCTTTC                                                                                               

  12   *Candida albicans*             PMA1     Adenosine triphosphatase            NW_139471.1   50 pg, 18 m    40 × 10ˆ6 CFU/mL, 20 m     Not tested       5 pg, 17 m     GACATCTTCTGGGATTGGGTGGG\       TTGCCGAATTTGCTTCCAGACCA\      ACAGTCTTTAAGACGAATAATGGGG   TCTTTGGGTGTTGCCAGAAAGAGAG   AGTTACTGCTATTGTTGAATCAC     TGGATCCATACATGGCATAA
                                                                                                                                                                           AAAGAATTATTTGTGTTAAGGGTG       AAATTTCCCAATGACCTT                                                                                                

  13   *Enterococcus casseliflavus*   VanC2    D-alanine--D-serine ligase          NG_048353.1   50 pg, 22 m    6 × 10ˆ3 CFU/mL, 32 m      Not tested       5 pg, 18 m     CATAGGGAGATGATTGGAGTGCA\       ATAGACCTCTCTTTGATCGGGAT\      TTCGATGCGCTAGTTGCTGA        CCCCCAGATGCTATGGATTGGTATT   CGCATATTTTTGGAGGCAATT       CGTATCCAACACCAGTGTC
                                                                                                                                                                           CGATACCCGTTTCTTTAGC            TTGTCGGATGTTTTCAGTTC                                                                                              

  14   *Enterococcus gallinarum*      VanC1    D-alanine--D-serine ligase          NG_048345.1   5 pg, 25 m     600 × 10ˆ3 CFU/mL, 26 m    Not tested       5 pg, 14 m     GTGGCAGGATCGTTTTCATAGCA\       TCGATCGTTTTATTCAAGACCATG\     GGGATAAAAGCAAAGTGGGAGCA     ATTCCCGATCTTTATCAAGCCGA     GCTCTTGCATCAACTTGC          AGCGCTGTTTTGTCAGTT
                                                                                                                                                                           TACCATGGGAATCGCTAG             GTTGTGATCCCTTTTGAAGAAC                                                                                            

  15   *Clostridium difficile*        TdcA     Toxin A                             NC_009089.1   Not tested     Not tested                 Not tested       Not tested     CCGCCAAAATTTTTTAGGGCTAATA\     AGATGTTGATATGCTTCCAGGTAT\     ATGTCAGATGCTGCAGCTAAATTTC   GAGACTAAATAAATTTTGTTATAG    AGTTTGTTTACAGAACAAGAGTT     ATTTTATCATTTCCCAACGGT
                                                                                                                                                                           TTTATAGTCAGGAGTTGTTAAATCG      TCTAGTCCAATAGAGCTAGGTC                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Quantification of purified genomic DNA from cultured hospital and ATCC sources for the In-Dx pathogens was performed through standard curve generation derived using LightCycler (**Figure [1](#F1){ref-type="fig"}**) and EBT-based color change analysis (**Figure [2](#F2){ref-type="fig"}**). Spiked purified DNA in urine and blood was analyzed with LightCycler to estimate primer amplification stability in human derived samples. Spiked whole cultured pathogen cells (except for *C. difficile*) were diluted into urine. Only *E. coli* was spiked into blood, concentrated using EconoSpin and quantified by LAMP analysis (**Table [1B](#T1b){ref-type="table"}**). Previous studies investigated whole spiked pathogens into blood for LAMP analysis using an alternate platform ([@B19]). Primers showing positive amplification from non-target DNA within 50 min were excluded from subsequent tests. Detection thresholds for primer sets using purified DNA ranged from 5 pg at 27 min (*mecA*) to 50 fg at 20 min (*Proteus mirabilis*) by LightCycler analysis (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). Isolates were positive from 5 to 500 pg at 35 min reaction time with EBT-LAMP analysis (**Table [1B](#T1b){ref-type="table"}**). Color change was detected for the *mecA* primers by EBT-LAMP analysis at 50 pg concentration of purified DNA at 35 min of incubation time (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). No EBT-LAMP samples were incubated greater than 35 min to avoid non-specific primer amplification.

![LightCycler Primer validation. Each In-Dx target organism's detection limit in log genomic copies per reaction well at five minute time intervals using the LightCycler method.](fmicb-08-02211-g001){#F1}

![Clinical sample processing and analysis. **(A)** *S. aureus* detection by EBT-color change from purple to blue-Tubes 1 and 2, negative, and Tubes 3 and 4, positive. **(B)** Positives, *S aureus* clinical sample amplification by thermocycler (first, pink tracing) and positive controls, *S aureus* amplification (second, blue tracing). **(C)** Cuvettes with positive (left) and negative (right) color change corresponding to spiked DNA samples. **(D)** Spectrophotometric analysis at 420 nm with corresponding positive control amplification (blue) and negative control (orange) at times 0--45 min for positive and negative samples (*n* = 3).](fmicb-08-02211-g002){#F2}

###### 

In-Dx targets organisms with sensitivity of assays in Colony Forming Units (CFU) × 10ˆ3 per mL of reaction derived from purified DNA, with *in vitro* dilution from urine and blood results for three technical replicates per target organism.

                                      Purified DNA    Urine detection           Blood detection                     Blood detection   EBT test sensitivity
  ---- ------------------------------ --------------- ------------------------- ----------------------------------- ----------------- ----------------------
  1    *Escherichia colt*             50 pg, 22 rri   110 × 10ˆ3 CFU/mL, 30 m   5,O00 × l0ˆ3CFU/mL,18 min           5 pg, 18 m        50 pg
  2    *Staphylococcus aureus*        500 fg, 25 m    80 × 10ˆ3 CFU/mL,30 m     l,4O0 × l0ˆ3CFU/mL,25 min           5 pg, 17 m        5 pg
  3    *mecA*                         5 pg, 27 m      40 × lOˆ3CFU/mL,38 m      1,530 × 10ˆ3 CFU/mL (2/3), 40 min   5 pg, 17 m        50 pg
  4    *Enterococcusfaecatis*         5 pg, *22* m    150 × 10ˆ3 CFU/mL, 30 m   30,500 × 10ˆ3 CFU/mL, 28 min        5 pg, 27 m        5 pg
  5    *Enterococcus faectum*         5 pg, 18 min    60 × 10ˆ3 CFU/mL,38 min   6,000 × 10ˆ3CFU/mL, 23 min          500 fa 30 m       500 pg
  6    *Klebsiella pneumoniae*        5 pg, 25 m      5O × l0ˆ3CFU/mL,30 m      900 × 10ˆ3 CFU/mL, 32 min           5 pg, 36 m        50 pg
  7    *Streptococcus agatactiae*     5 pg, 40 m      500 × 10ˆ3 CFU/mL, 50 m   430 × lOˆ3CFU/mL,30 min             5 pg, 30 m        5 pg
  8    *Staphylococcus eptdermtdis*   5 pg, 17 m      5 × 10ˆ3 CFU/mL, 20 m     1,700 × lOˆ3CFU/mL,20 min           5 pg, 13 m        50 pg
  9    *Streptococcus pyogenes*       5 pg, 20 m      8 × l0ˆ3CFU/mL,25 m       1 × l0ˆ3CFU/mL,18 min               5 pg, 14 m        50 pg
  10   *Proteus mirabills*            50 fg,20 m      20 × 10ˆ3 CFU/mL, 45 m    260 × 10ˆ3 CFU/mL, 36 min           50 pg, 26 m       50 pg
  11   *Pseudamanas aeruginosa*       5 pg, 15 m      30 × 10ˆ3 CFU/mL, 25 m    15,00O × l0ˆ3CFU/mL,18 min          50 p, 24 m        50 pg
  12   *Candida albicans*             50 pg, 18 m     40 × 10ˆ6 CFU/mL, 20 m    3,100 × 10ˆ3 CFU/mLI 1/3), I8 min   5 pg, 17 m        50 pg
  13   *Enteracoccus cassetlftavus*   5O pg, 22 m     6 × 10ˆ3CFU/mL, 32 m      3,900 × 10ˆ3 CFU/mL, 24 min         5 pg, 18 m        50 pg
  14   *Enteracaccus gallinarum*      5 pg, 25 m      600 × 1Oˆ3CFU/mL, 26 m    2,000 × 10ˆ3 CFU/mL, 18 min         5 pg, 14 m        50 pg
  15   *Clostridium difficile*        Not tested      Not tested                                                    Not tested        Not tested

Clinical Detection by In-Dx
---------------------------

In total, 239 samples were collected across culture types (31 blood, 122 urine, 73 mucocutaneous wound/swab, 11 sputum and two stool samples) from 229 consecutive prospectively enrolled patients with suspected clinical infection with samples analyzed both at the hospital and by In-Dx (**Table [2](#T2){ref-type="table"}**). Nine patients had two sample types analyzed by the In-Dx panel. Across blood, urine, wound/swab, sputum and stool samples the overall sensitivity of the In-Dx panel for detection of the target pathogens from 239 clinical samples was 76% with a specificity of 98%. The positive predictive value for all samples was 64% and negative predictive value was 99% (Supplementary Appendix [2B](#SM3){ref-type="supplementary-material"}).

###### 

In-Dx versus hospital culture results by culture type.

  Culture type   Samples (*n*)   True positive   True negative   False positive   False negative   Sensitivity   Specificity   PPV    NPV
  -------------- --------------- --------------- --------------- ---------------- ---------------- ------------- ------------- ------ ------
  Blood          31              1               429             1                3                25            99.8          50     99.3
  Urine          122             51              1608            44               5                91.1          97.3          53.7   99.7
  Swab           73              38              957             7                20               65.6          99.3          84.4   98
  Sputum         11              3               148             2                1                75            98.7          60     99.3
  Stool          2               1               1               0                0                100           100           100    100
  All            239             94              3143            54               29               76.4          98.3          63.5   99.1

A summary of data for performance of the In-Dx panel across culture types for the 15 In-Dx targets. Samples indicate total prospectively matched samples within each sample type. True positive indicates equivalent positive hospital and In-Dx results. True negative indicates equivalent negative results. False positive indicates negative by hospital culture and positive by In-Dx. False negative indicates positive by hospital culture and negative by In-Dx. Sensitivity, specificity, and positive and negative predictive values are expressed as percentages as described in section "Statistical Analysis."

Out of 31 matched blood cultures analyzed, hospital culture methods detected *E. coli* twice (In-Dx concordant detection in one of these two samples), MRSA once (no In-Dx detection), and one of two clinical blood culture samples taken from the same patient was positive for methicillin sensitive *S. epidermidis* (In-Dx negative). *E. coli* was detected from one sample by In-Dx for which one of two hospital blood cultures came back positive for unnamed micrococcus species. Sensitivity for positive detection of the 14 targets from blood using the filtration methodology was 25% (*n* = 1/4). Negative predictive value was 99.3% as three positive cultures were called negative by the In-Dx method used. It is very likely that the micrococcus and *S. epidermidis* positive cultures, both positive for only one of two blood collection tubes, are contaminants of little clinical value (Supplementary Appendix [1](#SM2){ref-type="supplementary-material"}).

For urine sample testing, 122 duplicate clinical samples were tested for presence of 15 molecular targets. 51 targets were equivalently detected by hospital and In-Dx across these matching culture samples. Negative agreement was present for 1715 tests (including *mecA* identification) (**Table [3](#T3){ref-type="table"}**). Overall sensitivity of the In-Dx panel for urine pathogen detection was 91% and specificity was 97%, with a positive predictive value of 54% and a negative predictive value of 99.7%. The In-Dx panel identified six target pathogens corresponding to hospital culture samples resulted as "normal flora" (**Table [3](#T3){ref-type="table"}**). In-Dx methods detected an additional 38 pathogen targets from clinical urine samples that were not positive by hospital cultures. Eight of these were *S. epidermidis* (C~t~ range 16--35 (Supplementary Appendix [1](#SM2){ref-type="supplementary-material"}), four with an associated positive *mecA* amplification. Another eight of these additional positives by In-Dx testing were *E. coli* (C~t~ range 10--28). *E. coli* was the most common uropathogen detected by both hospital culture (*n* = 36) and In-Dx methods (*n* = 48). Overall sensitivity for *E. coli* by In-Dx was 95% and Sp was 90%. *E. coli* identification by In-Dx was positive for an alternate pathogen by hospital culture results not targeted by the In-Dx panel four times (*Citrobacter koseri, Enterobacter cloacae, Candida* species (non-*albicans* non-*gabralta*), and *Klebsiella ornitholytica* one time each). The In-Dx did not identify a pathogen by direct In-Dx amplification that was found by hospital urine culture five times: twice for *E. coli*, and once each for *E. faecalis, E. faecium* and *S. agalactiae*. Each of these was confirmed positive by In-Dx from cultures grown from residual reserved clinical sample. In-Dx cycles to threshold positive ranged from 9 to 28 min for samples with concordant positive results and \>100,000 CFU/mL reported concentration (Supplementary Appendix [2A](#SM3){ref-type="supplementary-material"}).

###### 

Urinalysis comparison In-Dx versus hospital culture results by organism.

  Target result                  +/+ (TP)   +/- (FP)   -/+ (FN)   +/0 (FP)
  ------------------------------ ---------- ---------- ---------- ----------
  *Escherichia coli*             36         8          2          2
  *Staphylococcus aureus*        1          1                     
  *mecA*                                    8                     1
  *Enterococcus faecalis*        5          5          1          2
  *Enterococcus faecium*         1          1          1          
  *Klebsiella pneumoniae*        1          3                     
  *Streptococcus agalactiae*                1          1          
  *Staphylococcus epidermidis*   1          8                     
  *Streptococcus pyogenes*                                        
  *Proteus mirabilis*            1                                1
  *Pseudomonas aeruginosa*       3          1                     
  *Candida albicans*             2          1                     
  *Enterococcus casseliflavus*                                    
  *Enterococcus gallinarum*                 1                     
  **Sum**                        **51**     **38**     **5**      **6**

Urinalysis comparison, hospital culture results versus In-Dx thermocycler analysis: Column 1, + In-Dx/+ HCR 1-14, indicates true positive (FP) equivalent identification by both In-Dx panel and by hospital culture results for the 13 urinary tract infection species targets as well as

mecA

Column 2, + In-Dx / -HCR 1-14, indicates false positive (FP) clinical samples identified as positive by In-Dx and negative by hospital culture result. Column 3 indicates false negative (FN) with negative result by In-Dx and positive by hospital culture and Column 4 shows false positive (FP) samples found positive by In-Dx and called "Normal Flora" by hospital.

Among 73 duplicate wound and throat swab samples analyzed, sensitivity for presence of targets was 65.5% and specificity was 99.3% (**Table [4](#T4){ref-type="table"}**). *S. aureus* was the most frequently detected pathogen among wound and swab samples (*n* = 25 by hospital culture) and sensitivity for *S. aureus* detection by In-Dx methods was 68% with a specificity of 99%. Presence of *mecA* was found in association with detection of *S. aureus* and *S. epidermidis* as well as untargeted *Citrobacter koseri* (*n* = 1) and unidentified background flora. Targets missed by In-Dx by mucocutaneous swab analysis included *S. aureus* (*n* = 8), *mecA* (*n* = 4), *E. faecalis* (*n* = 2) and *S. agalactiae* (*n* = 2), *E. coli, K. pneumoniae, S. pyogenes* and *C. albicans* (*n* = 1 each) (**Table [4](#T4){ref-type="table"}**). In-Dx detected methicillin-resistant *S. epidermidis* in two samples which were not identified by hospital culture methods. Hospital methods identified three samples as "normal flora" but positive by In-Dx for *S. aureus* and *E. faecalis* once each (**Table [4](#T4){ref-type="table"}**).

###### 

Mucocutaneous swab culture results comparison by organism.

  Target result                  +/+ (TP)   +/- (FP)   -/+ (FN)   +/0 (FP)
  ------------------------------ ---------- ---------- ---------- ----------
  *Escherichia coli*             2          1          1          
  *Staphylococcus aureus*        17                    8          1
  methicillin resistance         6          2          4          
  *Enterococcus faecalis*                              2          1
  *Enterococcus faecium*                                          
  *Klebsiella pneumoniae*                              1          
  *Streptococcus agalactiae*     5                     2          
  *Staphylococcus epidermidis*   1          2                     
  *Streptococcus pyogenes*       4                     1          
  *Proteus mirabilis*            3                                
  *Pseudomonas aeruginosa*                                        
  *Candida albicans*                                   1          
  *Enterococcus casseliflavus*                                    
  *Enterococcus gallinarum*                                       
  **Sum**                        **38**     **5**      **20**     **2**

Mucocutaneous swab comparison, hospital culture results versus In-Dx thermocycler analysis across targets: Column 1, + In-Dx = + HCR 1-14, indicates true positive (TP) equivalent identification by both In-Dx panel and by hospital culture results for the 13 mucocutaneous infection species targets as well as

mecA

by target. Column 2, + In-Dx / -HCR 1-14, indicates false positive (FP) clinical samples with positive result by In-Dx and negative by hospital culture result. Column 3 indicates false negative (FN) results for In-Dx with positive result by hospital culture and negative by In-Dx. Column 4 shows false positive (FP) samples with positive results by In-Dx and identification as "Normal Flora" by hospital methods.

Eleven sputum samples were analyzed using the In-Dx panel. Pathogenic concentrations of *E. coli* (*n* = 1), *P. aeruginosa* (*n* = 1) and MRSA (*n* = 3) were detected by the panel. Of these, samples, agreement was reached for MRSA (*n* = 3) and *E. coli* (*n* = 1). In-Dx identified *P. aeruginosa* and *E. coli* one time each where hospital culture were called negative and normal flora, respectively. In-Dx did not detect *S. aureus* in one sputum sample identified as positive by hospital sputum culture methods. Negative agreement was reached for nine samples (Supplementary Appendix [2A](#SM3){ref-type="supplementary-material"}).

Only two stool samples were studied using direct amplification methods for detection of *C. difficile* (Supplementary Appendix [2A](#SM3){ref-type="supplementary-material"}). *C. difficile* toxin was identified by both direct amplification methods and hospital *C. difficile* toxin screening methods for one of these samples. Additional gastrointestinal pathogens can be added to help guide clinical decision making for infectious diarrheal complaints.

Color change detection by EBT-LAMP was tested as a secondary direct amplification testing technique for 12 clinical samples included in this study (8 urine samples, 3 mucocutaneous swabs and 1 stool sample tested for *C. difficile*). Eleven of these were confirmed positives by hospital testing including the stool sample positive for *C. difficile* toxin by hospital testing. None of the samples was *mecA* positive by hospital testing or EBT-LAMP analysis (Supplementary Appendix [2A](#SM3){ref-type="supplementary-material"}).

Sample Processing Time
----------------------

All LAMP reactions were completed within 120 min from start to finish per clinical sample. Time savings was gained when multiple samples were processed simultaneously in batches of up to three 96-well plates. Initial processing time was focused on filtration of blood, urine through EconoSpin spin Column filter tubes (∼10 min) and collection of sample from mucocutaneous swab tubes (∼3 min) followed by heat lysis at 95°C for 15 min. The lysed sample is then mixed with isothermal reaction reagents and pipetted onto 96-well plates preloaded with target primers, sealed and analyzed by either thermocycler (45 min run time with isothermal amplification) or visually (35 min isothermal amplification).

Discussion
==========

Diagnosing Pathogenic Infection in Humans
-----------------------------------------

Infection is one of the greatest problems faced by humanity and directly impacts care provided from every healthcare field. Care for the critically infected accounts for an enormous amount of health care resource expenditure. Every minute passing with untreated clinical infection can be reasonably expected to increase the total morbidity and mortality of the infected patient, while increasing the potential strength and pathogenicity of the infecting organism(s) as it survives, proliferates and spreads to other hosts while untreated. While the human body can overcome infection from most potential microbial invaders, those who are already sick or immunocompromised can fall victim to infection. Infections by dangerous pathogens are difficult to eliminate without proper antimicrobial therapy and spread readily among us. The length of time required for standard hospital testing of most microbial pathogens limits accurate and effective diagnosis and treatment of infection.

Methodologies for direct amplification of DNA and RNA sequences to target genetic regions of interest can allow rapid discrimination of microbial pathogens in a point-of-care time-frame. Utilizing either fluorescence detection by a real-time PCR instrument or naked-eye visual detection of color change from purple to blue using EBT-dye chelation, the direct amplification methods used here offer diagnostic capabilities equivalent to or improved compared to the gold standards of clinical microbial pathogen identification, but in a significantly reduced time frame and with lower resource use.

Our results provide evidence that direct amplification methodologies can overcome many limitations of detection of infectious pathogens. We have shown that low but clinically relevant pathogen loads do not appear to limit detection of pathogens directly from urine, wound, sputum and stool samples. Relatively high sensitivities were found for the pathogens targeted by In-Dx, especially with urine samples for which 3 mL of the clinical urine sample was used per panel run.

In-Dx Identifies of Pathogens across Human Sample Types
-------------------------------------------------------

Our methods are robust yet sensitive to pathogen concentrations from samples across a diverse set of tissue types. The organisms targeted by In-Dx account for \>70% of positive clinical blood and \>85% of positive urine culture results in 2013 (Supplementary Table [1](#SM4){ref-type="supplementary-material"}). Sufficient clinical sample (\>5 mL) is available from most urinalysis specimens for a great deal of molecular testing. Positive identification is clear from most samples after 20 min by isothermal amplification. Strongly positive clinical samples with \>100,000 CFU/mL by culture averaged a Ct value of 14.4 min by LightCycler analysis (*n* = 39). It does not seem likely by these results that false positive of clinical pathogens by In-Dx is a problem. The 91% overall sensitivity of the In-Dx panel was higher for urine samples when compared to culture results from two different hospital institutions. False negative detection by In-Dx was low for the targeted organisms as compared to hospital were rare compared to hospital culture (5/121) (Supplementary Appendix [2A](#SM3){ref-type="supplementary-material"}). Reasons for failure of these samples are unknown but one (Pt ID 222) was possibly are due to reaction error as subsequent repeat testing from culture was positive for *E. faecalis* as indicated by hospital culture. Cultures did not show growth for other false negative samples.

Although a low sensitivity (25%) was present for blood samples, the clinical sample size is too low to make confident predictions about utility of the process used here for direct amplification. Many of our clinical samples were collected from patients with stable vital signs and of a mild to moderate state of illness. *In vitro* testing suggests that Purple Top EDTA Blood Collection tubes are best for analysis using In-Dx methods. A low abundance of target template is expected from the small amount of blood sampled for direct amplification analysis. LAMP methods have been used successfully to identify pathogens from blood that is already pre-cultured and shows signs of colony growth. No studies appear to have been published to date in which direct amplification from whole blood at the point-of-care is performed. We are currently working to lower our threshold for identification with alternate processing methods to enable detection of bacteremia.

More critically ill patients would reasonably be expected to carry a higher concentration of pathogens per mL of circulating blood. The median Glasgow Coma Score among patients was 15 (out of 15) with an average shock index (heart rate/ systolic blood pressure) of 0.71, an average mean arterial pressure (diastolic blood pressure + 1/3 (systolic blood pressure -- diastolic blood pressure)) of 99 and an average lactic acid concentration of 1.68 mg/dl. Therefore, a low percentage of these patients would be likely to have significant bacteremia. A larger sample size from a cohort of more critically septic patients will likely improve results of direct blood testing by the In-Dx method.

The sensitivity threshold and range displayed by our direct amplification methods appears to correlate much more strongly with "moderate" or "many" laboratory reported results for wound and sputum samples, and to \>50,000 CFU/mL for urine output results. Outputs from clinical urine samples from Sparrow Hospital are presented in concentration ranges from 10,000 to 25,000, 25,000 to 50,000, 50,000 to 100,000 and \>100,000 CFU/mL. *E. coli* was not detected twice from urine (once at a concentration of 10,000--25,000 CFU/mL, once \>100,000 CFU/mL. 10,000--25,000 CFU/mL may be below the limit of detection for the direct amplification method for urine, at least for this probe set, though the 21 additional pathogens identified by In-Dx testing and subsequently confirmed in culture argue toward potential under-detection by hospital clinical methods.

Specific Primer Sets Reveal Specific Pathogens
----------------------------------------------

Results from direct amplification testing of sputum samples show great promise for LAMP methods to rapidly reveal potential infectious respiratory pathogens including *P. aeruginosa*. A panel with inclusion of more common respiratory pathogens will provide a valuable infection diagnostic tool. More samples are needed to fully address detection capabilities for sputum samples.

*Staphylococcus aureus* and MRSA were the most under-detected clinical targets. These pathogens are of the highest clinical abundance and were missed on first pass POC testing about 30% of the time. Lactate dehydrogenase was chosen due to its relative low homology to all other known genetic sequences explored *in silico* and presumptive high abundance of mRNA and DNA for amplification given its core metabolic genetic function. It is noted that *mecA* detection lags approximately 4 min in each case likely reflecting lower marker abundance relative to LDH. This apparent decreased sensitivity translates to further under-detection of *mecA* by EBT color changed analysis from samples found to be positive by LightCycler analysis. No detection of mecA has been noted on a MRSA sample with the EBT method in this study. Sensitivity *in vitro* shows detection of 600 pg purified DNA per reaction at 35 min with the EBT method.

Numerous reasons may account for under-detection of wound swabs. In most wound swab samples collected the duplicate second, third or even fourth swab was sent for analysis by In-Dx. Clinical sample analysis preference was always given toward hospital testing to avoid potential underdiagnoses of patient infection. Often, the duplicate sample for In-Dx analysis had a very small amount of clinical sample to be analyzed as a result of decreased sample availability following replicate collections.

The amount of clinical swab saturation with sample appears to be directly correlated with direct amplification findings for positive samples. Although very little sample is needed, limits are certainly present for detection. All hospital clinical *S. aureus* and MRSA sample positives missed by the first pass using In-Dx were retested on cultures grown in trypticase soy broth and were found to confirm hospital culture findings. All clinical samples were grown in culture and those with positive growth in trypticase soy broth were retained and frozen for retesting. It is also possible that the lower sensitivity of detection from mucocutaneous swab samples is due to interfering substances present with the clinical sample. To determine the influence of interfering factors on reactions an internal control PCR set should be included in future studies.

Advantages to the rapid diagnostic methods employed here include amelioration of appropriate antimicrobial strategy selections including selection of antibiotics with a high degree of specificity for eradication of infection. For example, *E. coli* was 97% sensitive to nitrofurantoin and 89--97% sensitive to cephalosporin antibiotics versus lower sensitivities for more commonly prescribed empiric urinary tract infection antimicrobials such as trimethoprim/sulfamethoxazole (78%) and fluoroquinolones (79--80%) (Supplementary Table [2](#SM5){ref-type="supplementary-material"}: Sparrow and McLaren of Greater Lansing Hospital Antibiotic Sensitivity Summary 2015). Monomicrobial pathogenic infections by *E. coli* accounted for 48.96% of all urinary tract infections (*n* = 9714) and 9.56% (*n* = 261) of bloodstream infections in through Sparrow Hospital clinical laboratory testing (Supplementary Table [1](#SM4){ref-type="supplementary-material"}). Similar precision with antibiotic prescription selection would be much easier to enact based on the results seen with direct amplification. As the burden of antibiotic resistance transmission increases, particularly within strains of enterobacteriaceae, precise antibiotic prescription should be of increasing importance in antimicrobial therapy decision making.

Polymicrobial detection from clinically infected sources is equal or greater to that of protracted culture methods. Positive polymicrobial cultures from clinical wound samples often revealed microbes of questionable clinical relevance including *Corynebacterium* species, micrococcus species, and peptostreptococcus species, all of which are likely non-pathogenic normal flora. General microscopic identification results with Gram stain and cell morphology but without genus and species designation assigned as final result outputs are generally presented without associated antibiotic sensitivity and resistance results. This begs the question of clinical relevance, especially when reported concentrations are few, rare or moderate after 4--6 days of culture and modification of antibiotic therapy will continue to be empirical at best.

EBT-based color change reactions offer the strengths of detection by direct amplification without the potential limitations present with advanced electronics utilized with a thermocycler based platform. Reactions are performed with a heating block capable of reaching isothermal amplification temperatures, an ice bath, and an individual who can detect color change from purple to blue. Limitations include longer incubation time to detect low abundance targets (such as resistance genes including *mecA*) when clinical sample volume is limited. A longer amplification time (35-45 min) can be used on a separate plate to identify lower abundance genes. To prevent non-specific amplification from species-specific metabolic genes and increase chances of false positive identification all targets running concurrently must amplify in the same timeframe for naked eye detection of color change. When samples are pre-cultured for increased target abundance, such template concentration-restricted scarcity can be overcome.

Our methods offer advantages in speed, sensitivity, specificity, scalability, flexibility in target selection, and conservation of resource utilization. Limitations revealed in the sample population studied include low sensitivity for bloodstream infection. This hindrance is due to a low number of samples studied, low positive rate among the samples studied, variability in the types of samples received (included were EDTA and Bactec aerobic culture bottles). Additionally, only 3 mL of blood was processed to test against the 14 targets. Processing a larger volume of blood for In-Dx could aid in clearing the threshold for pathogen detection directly from these samples for potential point-of-care blood testing. Alternative methodologies for target extraction from bloodstream including nanoparticles and microbeads and premixing reagents with stabilization of reactions at room temperature will help in ease of processing to increase potential for bedside diagnostics by clinical staff with limited training.

Direct amplification of target nucleic acids utilizing isothermal PCR techniques can be adapted toward direct and rapid processing of clinical samples for accurate detection of the primary pathogens responsible for clinical infection across a wide variety of clinical types at the point-of-care. Further testing on additional samples can elucidate testing limitations and generalizability among the pathogens to allow a paradigm change in clinical microbiological testing and infection surveillance and control.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

All experimentation with human samples was conducted on samples taken from consenting patients or their designated representative following the Human Research Protection Program and performed in accordance with institutional regulations after pertinent review and approval by the Institutional Review Board at Michigan State University (East Lansing, MI, United States), Sparrow Hospital (Lansing, MI, United States), and McLaren of Greater Lansing Hospital (Lansing, MI, United States) Investigational Review Boards MSU IRB\# C13-033F. Written consent was obtained from healthy individuals that donated blood, urine, and sputum samples. Cultured bacterial isolates used for spike-in controls were determined to be non-human subject research as described in a previous study MSU IRB\# 12-706 ([@B19]). Patient clinical samples were collected between 02-22-2015 and 06-22-2016.

Study Design
------------

Candidate isothermal amplification primers were generated from review of literature and through NCBI BLAST analysis of potential candidate gene regions ([@B1]). LAMP primers were designed using PrimerExplorer V4 software based on consensus sequences obtained for target genes ([@B10]). Sensitivity, specificity and reproducibility for LAMP primers were first evaluated using purified genomic DNA isolated from known cultured strains of target pathogenic microbes with known hospital antibiotic sensitivity and resistance results as previously described ([@B19]). The strongest performing primer sets for each target gene were evaluated against unprocessed duplicate clinical culture samples on 96-well plate format using real-time PCR detection by Roche LightCycler 96 System analysis and visual discrimination of color change of reactions in the presence of Eriochrome Black Dye (EBT) after incubation on a 96-well plate-adapted heat block. The LAMP assays for detection of 14 clinical pathogens as well as the *mecA* gene were compared with conventional hospital culture and PCR-based assays for sensitivity and specificity of detection directly from clinical samples obtained in the Emergency Department from consenting patients at two regional hospitals, Sparrow Hospital, a Level One Trauma Center, and McLaren of Greater Lansing Hospital, a Level Two Trauma Center, both in Lansing, MI. Samples were first analyzed using LightCycler amplification and a subset were run using EBT-dye methods. Clinical samples with less than 6 mL of urine or an undetectable signal by LightCycler were excluded from EBT analysis.

Primer Design and Loop-Mediated Isothermal Amplification with Genomic DNA
-------------------------------------------------------------------------

A six-primer system was employed for the LAMP reaction detection of clinical pathogens. Primer targets were selected from literature or designed using PrimerExplorer V4^[1](#fn01){ref-type="fn"}^ online software. Between two and nine primer sets, including a Forward 3 (F3), Backward 3 (B3), Forward Inner Primer (FIP), Backward Inner Primer (BIP), Loop Forward (LF) and Loop Backward (LB) for a total of six primers per target, were developed for each strain and optimized for sensitivity and specificity. Each primer set was tested with purified genomic DNA to achieve detection of ≥5 pg within 30 min. The most sensitive and specific primer set for each microbial target was selected for clinical sample detection (**Table [1](#T1){ref-type="table"}**). For generating standard curves, genomic copies per reaction for each isolate was estimated based on mass of gDNA used per reaction and the average genome size for the respective species.

Hospital Culture Analysis
-------------------------

Culture identification was performed using Siemens Microscan (Beckman Coulter, Inc.), BD Phoenix Automated Microbiology System (Becton, Dickinson and Company), or biochemical tests. Prior to revival of clinical samples for primer validation, isolates were stored in 15% glycerol stocks at -80°C. Isolates were revived by growing on tryptic soy broth (TSB) media overnight at 37°C (no agitation) and serial diluted in 1× Phosphate Buffered Saline (PBS). Ten microliters of each serial dilution was plated on trypticase soy agar (TSA) plates (in triplicate) and colony forming units (CFU) were counted following 24 h of incubation at 37°C.

Microbial culture samples used for primer validation studies included Methicillin-resistant *S. aureus, S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Escherichia coli*, Methicillin-resistant *S. epidermidis, Proteus mirabilis, Klebsiella pneumoniae, C. difficile* and *Candida albicans*. Each was a validated clinical culture sample from Sparrow Hospital. *Enterococcus casseliflavus (ATCC: 25788), Enterococcus gallinarum (ATCC: 49673)*, and *Pseudomonas aeruginosa (ATCC: 10145)* are from American Type Culture Collection (ATCC, Manassas, VA, United States).

DNA Extraction from Microbial Strains for Primer Validation with Thermocycler and Eriochrome Black T Dye
--------------------------------------------------------------------------------------------------------

Extraction of DNA from bacterial strains for initial primer testing was performed with a DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer's instructions. 1.5 mL of bacteria growth culture was used for each strain. The elution volume was 100 μL and the concentration was finally adjusted to 5 ng/μl. Ten-fold serial dilutions of purified genomic DNA from 500 pg/μL to 5 fg/μL for each strain were used for DNA standard curve control generation (**Figure [1](#F1){ref-type="fig"}** and Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

Minimum concentration for detection was determined for reactions in the presence of Eriochrome Black T dye for ten-fold serial dilutions of purified genomic DNA from 500 pg/μL to 5 fg/μL for each strain with visual and spectrophotometric analysis at 5 min intervals from 0 to 45 min to determine EBT sensitivity standard curve generation (**Figure [2](#F2){ref-type="fig"}**).

EBT color measurement was performed by spectrophotometer at the wavelengths 380, 400, 420, and 475 nm. Seventy microliter LAMP reaction systems were employed for this purpose. After the LAMP reaction, 64 μL of reaction mixture was taken to the test cuvettes in which preload with 448 μL of water (eight times dilution). After mixing well, absorbance values of the cuvettes were read by a GENESYS 10 Series spectrophotometers from Spectronic Unicam (**Figure [2](#F2){ref-type="fig"}**).

Clinical Specimens
------------------

A total of 239 duplicate clinical blood (*n* = 27), urine (*n* = 122), wound/throat swab (*n* = 73), expectorated sputum (*n* = 16), stool (*n* = 2) samples from 229 consecutive consenting Emergency Department patients with suspected infection were collected over a period of 16 months from McLaren of Greater Lansing Hospital and Sparrow Hospital. No cerebrospinal fluid samples met inclusion criteria for this study. All clinical samples used in this study were stored at 4°C immediately after collection until nucleic acid template preparation. The stored samples were processed within 24 h of clinical collection time. Clinical template extracts were applied to LAMP reaction immediately following template preparation. Clinical samples were excluded in cases of suspected or confirmed external contamination and or other sample collection and processing problems. All clinical samples from patients with missing or erroneous consent forms were discarded (Supplementary Appendix).

Nucleic Acid Template Preparation from Clinical Blood, Urine, Wound, Sputum, and Stool Samples
----------------------------------------------------------------------------------------------

### Blood Samples

Three milliliter of blood from each Red-top BD Vacutainer Plus Venous Blood Collection Tube Serum Clot Activator, Purple-top BD Vacutainer K2 EDTA Venous Blood Collection Tube, or BD BACTEC Plus Aerobic/F blood culture solution sample, was taken and passed through an EconoSpin Column for crude DNA extraction. Hundred microliter of water was then added to the column within a collection tube and heated on a heating block at 95°C for 15 min.

### Urine Samples

Three microliter of whole urine from each clinical sample was passed through an EconoSpin Column for collection of genetic material. Next, 100 μl of water was resuspended on the column filter and heated on a heating block at 95°C for 15 min.

### Wound/Swab Samples

Hundred microliter of liquid was added and then aspirated from the bottom of a BD BBL CultureSwab EZ tube using 200 μl pipettes and transferred to 1.5 mL Eppendorf tube. Repeated aspirations were needed to extract 100 μl from most tubes. Sample was then heated on a heating block at 95°C for 15 min.

### Stool and Sputum Samples

Four hundred microliter of sample was transferred directly from clinical sterile hospital collection container to 1.5 mL Eppendorf tube. This sample was then heated on a heating block at 95°C for 15 min.

After heating, 1 μl of template from each clinical sample type was added per 10 μl reaction well in a 96-well plate format and analyzed on by LAMP Thermocycler and Eriochrome Black T (EBT) colorimetric change.

Thermocycler SYTO-82 Reactions
------------------------------

LAMP primers were pre-dispensed in 96-well plates to result in a final concentration of 1.6 μM FIP primer, 1.6 μM BIP primer, 0.8 μM LF primer, 0.8 μM LB primer, 0.2 μM F3 primer and 0.2 μM B3 primer. One target assay was included per well. LAMP Thermocycler reactions were carried out on Roche LightCycler 96 System in 10 μl volume. The LAMP reaction mixture contained 1X Isothermal Amplification Buffer (New England BioLabs), 6 mM magnesium sulfate, 0.64 Unit/μl Bst 2.0 DNA polymerase (New England BioLabs), 20 μM Syto 82 (Molecular probes/Life Technologies), 0.4% Pluronic F-68, 1 μg/μl Bovine Serum Albumin (BSA), 350 μM of each dNTP (Invitrogen), and 1 μl Template.

All primers were synthesized by Integrated DNA Technologies, Inc. The LAMP LightCycler reactions proceeded at 63°C for 40 min. Each target was tested in triplicate with one positive control and one no-template control (5 wells per target). Targets 1--15 were always included in clinical blood, urine, mucocutaneous swab, and sputum analysis. *C. difficile* was the only target for clinical stool samples (*n* = 2).

Eriochrome Black T (EBT) Clinical Sample Reactions
--------------------------------------------------

A subset of positive clinical samples identified by the LightCycler method was tested in 96-well PCR plate format using the colorimetric color indicator azo dye Eriochrome Black (*n* = 12). EBT is an indicator that causes a color change of solution according to calcium or magnesium concentration. As Mg^2+^ concentration decreases during a LAMP reaction in the presence of EBT, the solution changes from purple to blue. Color change measurements were identified visually and using a spectrophotometer (Genesys 10 UV) with measurements recorded at 5 min intervals from 0 to 45 min at 380, 400, 420, and 475 nm wavelengths. Identical LAMP primers used for LightCycler reactions (1.6 μM FIP primer, 1.6 μM BIP primer, 0.8 μM LF primer, 0.8 μM LB primer, 0.2 μM F3 primer and 0.2 μM B3 primer) were pre-dispensed into 96-well plates, and each 10 μL reaction mixture contained 10X Isothermal Amplification Buffer (New England BioLabs), 6 mM magnesium sulfate, 0.64 Unit/μl Bst 2.0 DNA polymerase (New England BioLabs), Eriochrome Black 75 μM (Sigma Aldrich), 0.4% Pluronic F-68, 1 μg/μl BSA, 350 μM of each dNTP, and 1 μl Template. One target assay was included per well. The LAMP reaction mixture was incubated at 63°C for 40 min on a 96-well block heater (Thermo Scientific Compact Digital Dry Bath/Block Heater) followed by immediate immersion in an ice water bath (to stop the reaction and decrease condensation on clear sealing tape) for 1 min before immediate visual color change discrimination from purple to blue by one or more non-color blind human examiners. Colorimetric detection results remained stable for at least 24 h. As with real-time cycler analysis, each target was tested triplicate with one positive control and one negative no template control (5 wells per target), targets 1--15 were always included in clinical urine, mucocutaneous swab and stool analysis and *C. difficile* was the only target for clinical stool samples.

Data Analysis
-------------

For real-time LAMP analysis, cycles to threshold (C~t~) was calculated from the starting point of the amplification signal curve increased 0.01 (arbitrary units) above the baseline signal calculated by LightCycler default autoanalysis. Amplification of at least two of the triplicate wells per target was needed for determination of a sample as positive. The latest of the triplicate positives for each sample was recorded as the amplification time for this sample. A cutoff of 40 cycles (53 s per cycle) was used to minimize false-positive and non-specific primer amplification. The only exception was for *C. difficile* primers which were found to amplify later. The cutoff for the *C. difficile* primer set was set to 40 min (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

For EBT dye analysis, spectrophotometric data was recorded by readings for positive and negative samples at 5 min intervals from 0 to 45 min at wavelengths 380, 400, 420, and 475 nm. Amplification of at least two of the triplicate wells per sample was used for determination of positive. The cutoff of 45 cycles was used to minimize false-positive and non-specific primer amplification (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}).

Statistical Analysis
--------------------

Clinical data corresponding to duplicate samples obtained for LAMP analysis were abstracted by retrospective chart review. Patient characteristics and laboratory values, including hospital culture results by organism isolated across culture types, were recorded. All clinical samples with hospital culture or equivalent testing and with a corresponding duplicate sample for LAMP testing were included in analysis (see Appendices: 1-All data, 2-Matched Clinical Data).

Standard measurements for statistical analysis were used to calculate:

Sensitivity (SE) or true positive rate (TPR)

SE = True Positive (TP) / (True Positive (TP) + False Negative (FN))

Specificity (SP) or true negative rate (TNR) = N targets -- TP -- False Positive (FP) - FN

SP = True Negative / (TN + FP)

Precision or positive predictive value (PPV)

PPV = TP / (TP + FP)

Negative predictive value (NPV)

NPV = TN / (TN + FN)

Sensitivity for each organism was determined based on positive findings on In-Dx in comparison to hospital methods abstracted from clinical results.

Thermocycler SYTO-82 Reaction Analysis
--------------------------------------

Threshold cycle (C~t~) was calculated as time in which signal increased 0.01 arbitrary units above the original signal for real-time analysis. One cycle is completed every 53 s. Overall, results were considered positive if two out of three wells exhibited amplification.

Eriochrome Black T (EBT) Reaction Analysis
------------------------------------------

The threshold for identification of positive amplification was positive color change from purple to blue in at least two out of three wells for each gene target. Results were determined by visual discrimination by one or more non-color blind observers who were blinded to the targets in each well. All plates were read immediately after reaction completion.
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